PET predicts GI cancer's early response to chemo

Article

F-18 FDG-PET can tell which patients will respond to neoadjuvant chemotherapy for advanced adenocarcinoma of the esophagogastric junction only two weeks after they begin treatment, according to a study released at the 2007 SNM meeting.

F-18 FDG-PET can tell which patients will respond to neoadjuvant chemotherapy for advanced adenocarcinoma of the esophagogastric junction only two weeks after they begin treatment, according to a study released at the 2007 SNM meeting.

German investigators evaluated 110 patients who underwent FDG-PET to assess response to chemotherapy. Researchers defined as responders patients with 35% or greater decrease in tumor standardized uptake value after two weeks of treatment. Responders went on chemotherapy for 12 weeks before surgery, while nonresponders discontinued treatment and proceeded to surgery right away.

Researchers found statistically significant evidence (p < .002) that responders survived about twice as long as nonresponders during a median follow-up of 2.3 years.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.